Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30700061 | 0.94 | CTSS (0.47) | CTSSCTSKCTSLCTSBAAK1 | |
| SCHEMBL23824539 | 0.92 | CTSL (0.41) | CTSL | |
| SCHEMBL8278850 | 0.92 | CTSL (0.41) | CTSL | |
| SCHEMBL23824538 | 0.92 | CTSL (0.41) | CTSL | |
| SCHEMBL23782052 | 0.89 | CTSL (0.50) | CTSLCTSB | |
| SCHEMBL29063289 | 0.89 | CTSL (0.54) | CTSSCTSKCTSLCTSB | |
| SCHEMBL29063284 | 0.89 | CTSL (0.54) | CTSSCTSKCTSLCTSB | |
| SCHEMBL29062838 | 0.89 | CTSL (0.54) | CTSSCTSKCTSLCTSB | |
| SCHEMBL30009598 | 0.89 | CTSL (0.54) | CTSSCTSKCTSLCTSB | |
| SCHEMBL8278007 | 0.89 | CTSL (0.42) | CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536680-A1 | RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOF | The Governors of the University of Alberta (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-20230399296-A1 | RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOF | THE GOVERNORS OF THE UNIVERISTY OF ALBERTA (CA) | 2023-12-14 | — | — | US | disclosed |
| US-20230399296-A1 | RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOF | THE GOVERNORS OF THE UNIVERISTY OF ALBERTA (CA) | 2023-12-14 | — | — | US | disclosed |
| WO-2023235970-A1 | RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023235970-A1 | RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399296-A1 | RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOF | SARS1, POLRMT, RNASEH1 | CTSS 559/4885CTSK 1256/4885CTSL 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.